Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Autoimmune Disorders

Free Subscription Articles published in Kidney Int Retrieve available abstracts of 130 articles: HTML format

Single Articles

March 2028
1. ROVIN BH, Barratt J, Cook HT, Noronha IL, et al
   Complement inhibitors and B-cell modifying agents for IgA nephropathy- a KDIGO commentary.
   Kidney Int. 2028 Mar 31:S0085-2538(26)00213-9. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   July 2026
2. FLOEGE J
   The 4-hit hypothesis in IgA nephropathy is getting more complex.
   Kidney Int. 2026 Jul 6:S0085-2538(26)00502-8. doi: 10.1016/j.kint.2026.
   PubMed    
   
   
   
3. SUZUKI H, Novak J
   Galactose-deficient IgA1 plays a critical role in the formation of pathogenic immune complexes in IgA nephropathy.
   Kidney Int. 2026 Jul 6:S0085-2538(26)00508-9. doi: 10.1016/j.kint.2026.
   PubMed    
   
   
   
4. ZHANG Y, Barratt J, Zhao MH, Zhang H, et al
   Beyond galactose deficiency: redefining pathogenic IgA in IgA nephropathy.
   Kidney Int. 2026 Jul 6:S0085-2538(26)00492-8. doi: 10.1016/j.kint.2026.
   PubMed    
   
   
   
5. FANOURIAKIS A, Teng YKO
   Asymptomatic serologic reactivation in patients with lupus nephritis in clinical remission: to treat or not to treat?
   Kidney Int. 2026;110:39-41.
   PubMed     Abstract available
   
   
   June 2026
6. BURBELO PD, Howard L, Caza TN, Borza DB, et al
   Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy.
   Kidney Int. 2026 Jun 18:S0085-2538(26)00497-7. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   
7. BASSANESE G, Weingarten AM, Mancuso MC, Levart TK, et al
   Real-world outcomes of pegcetacoplan treatment in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
   Kidney Int. 2026 Jun 15:S0085-2538(26)00433-3. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   
8. SEIKRIT C, Floege J
   Beyond galactose-deficient IgA1: reconsidering IgA2 as a pathogenic driver in IgA nephropathy.
   Kidney Int. 2026;109:1091-1094.
   PubMed     Abstract available
   
   
   
9. KURZHAGEN JT, Laqua W, Schiffer M, Grieshaber-Bouyer R, et al
   T-cell engagers mediate deep cell depletion beyond autoimmunity.
   Kidney Int. 2026;109:1081-1084.
   PubMed     Abstract available
   
   
   May 2026
10. SHEN X, Shu C, Dong Y, Li J, et al
    Therapeutic Efficacy and Antigenicity of a Novel PEGylated IgA Protease in Preclinical Models of IgA Nephropathy.
    Kidney Int. 2026 May 22:S0085-2538(26)00401-1. doi: 10.1016/j.kint.2026.
    PubMed     Abstract available
    
    
    
11. FURIE R, Anders HJ, Bertsias G, Delgado A, et al
    A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis.
    Kidney Int. 2026 May 21:S0085-2538(26)00397-2. doi: 10.1016/j.kint.2026.
    PubMed     Abstract available
    
    
    
12. KURZHAGEN JT, Laqua W, Schett G, Grieshaber-Bouyer R, et al
    Tiny warriors, big impact: targeted immunotherapy in kidney diseases.
    Kidney Int. 2026;109:869-882.
    PubMed     Abstract available
    
    
    
13. PAUTRAT N, Raimbourg Q, Cohen C
    The Case | Febrile pancytopenia with mixed cryoglobulinemia and glomerulonephritis in a traveler.
    Kidney Int. 2026;109:1045-1046.
    PubMed    
    
    
    April 2026
14. ROVIN BH, Furie R, Malvar A, Aranow C, et al
    Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.
    Kidney Int. 2026 Apr 27:S0085-2538(26)00307-8. doi: 10.1016/j.kint.2026.
    PubMed     Abstract available
    
    
    
15. RIZK DV
    Predicting steroid treatment benefit in IgA nephropathy: are we ready for precision care?
    Kidney Int. 2026;109:649-651.
    PubMed     Abstract available
    
    
    
16. PERKINS GB, Naesens M
    Nobel prize-winning Treg cells in autoimmune kidney diseases and transplantation.
    Kidney Int. 2026;109:624-629.
    PubMed     Abstract available
    
    
    
17. COLOMBAT M, Dalloux-Chioccioli J, Bancal E, Mouton E, et al
    Laser microdissection coupled to mass spectrometry is more sensitive than immunohistochemistry in diagnosing phospholipase A2 receptor-positive membranous nephropathy.
    Kidney Int. 2026;109:796-797.
    PubMed    
    
    
    March 2026
18. YAP DYH, Chan SCW, Wong PYH, Wong S, et al
    A prospective multi-center randomized controlled trial preemptive increase in immunosuppression for asymptomatic serological reactivation in patients with lupus nephritis in clinical remission.
    Kidney Int. 2026 Mar 27:S0085-2538(26)00238-3. doi: 10.1016/j.kint.2026.
    PubMed     Abstract available
    
    
    
19. AL-RABADI L, Storey A, Abuelsamen T, Takayama S, et al
    Serine Protease HTRA1 is a Common Autoantigen in Membranous Nephropathy in Patients of 80 Years and Older.
    Kidney Int. 2026 Mar 27:S0085-2538(26)00237-1. doi: 10.1016/j.kint.2026.
    PubMed     Abstract available
    
    
    
20. PETIT-PAITEL A, Bihl F, Lambeau G
    Autoimmunoglobulin-triggered extracellular vesicles as New Players in Membranous Nephropathy: Friends or Foes?
    Kidney Int. 2026 Mar 26:S0085-2538(26)00231-0. doi: 10.1016/j.kint.2026.
    PubMed    
    
    
    
21. LIU WB, Hu HK, Liu W, Rui HL, et al
    Anti-PLA2R1 IgG-mediated podocyte PLA2R1 cleavage drives glomerular subepithelial immune complex deposition in membranous nephropathy.
    Kidney Int. 2026 Mar 13:S0085-2538(26)00164-X. doi: 10.1016/j.kint.2026.
    PubMed     Abstract available
    
    
    
22. LI R, Ma Y, Xie X, Qin A, et al
    Evidence from multicenter clinical studies and humanized mouse models indicates that glomerular mesangial IgA2 deposition contributes to the pathogenesis of IgA nephropathy.
    Kidney Int. 2026 Mar 13:S0085-2538(26)00161-4. doi: 10.1016/j.kint.2026.
    PubMed     Abstract available
    
    
    
23. QIN Z, Weiqiang L, Dajin C, Rending W, et al
    Empagliflozin-associated Armanni-Ebstein lesions in IgA nephropathy.
    Kidney Int. 2026 Mar 12:S0085-2538(26)00058-X. doi: 10.1016/j.kint.2025.
    PubMed    
    
    
    
24. CARAVACA-FONTAN F, Praga M
    The expanding role of complement inhibitors in the treatment of IgA nephropathy.
    Kidney Int. 2026;109:438-441.
    PubMed     Abstract available
    
    
    
25. AL JURDI A, Kotton CN, Lafayette R
    Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors.
    Kidney Int. 2026;109:484-488.
    PubMed     Abstract available
    
    
    February 2026
26. XIA X, Long C, Chen W, Yao X, et al
    METTL3-targeted intervention on nuclear factors RORA/RORgammat suppressing pathogenic T helper 17 cell differentiation and restores kidney damage in lupus nephritis.
    Kidney Int. 2026 Feb 19:S0085-2538(26)00133-X. doi: 10.1016/j.kint.2026.
    PubMed     Abstract available
    
    
    January 2026
27. PATALE DN, Raju S, Ramesh A, P S P, et al
    Genitourinary tuberculosis in lupus nephritis.
    Kidney Int. 2026 Jan 29:S0085-2538(25)01034-8. doi: 10.1016/j.kint.2025.
    PubMed    
    
    
    
28. LIU X, Wang L, Lin M, Jia N, et al
    Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA(+)beta7(+) cells in IgA nephropathy.
    Kidney Int. 2026 Jan 20:S0085-2538(26)00010-4. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
29. CANNEY M, Shan S, Er L, Billot L, et al
    A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy.
    Kidney Int. 2026 Jan 20:S0085-2538(26)00005-0. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
30. KLING L, Kettritz R
    Similar and yet not quite the same: unmasking distinct type I interferon signatures in ANCA vasculitis.
    Kidney Int. 2026;109:34-37.
    PubMed     Abstract available
    
    
    
31. TOMAS NM
    Toward precision immunotherapy in nephrology: 1 step forward.
    Kidney Int. 2026;109:31-33.
    PubMed     Abstract available
    
    
    
32. BRILLAND B, Despre M, Khatri R, Quemeneur T, et al
    A stronger type I interferon signature distinguishes ANCA-associated vasculitis phenotypes and predicts kidney prognosis.
    Kidney Int. 2026;109:139-159.
    PubMed     Abstract available
    
    
    
33. ZHU Z, Ren K
    Probing the surrogate validity of proteinuria thresholds in C3 glomerulopathy/immune-complex membranoproliferative glomerulonephritis: unresolved biases and mechanistic gaps.
    Kidney Int. 2026;109:225.
    PubMed    
    
    
    December 2025
34. BARBOUR SJ, Hladunewich MA, McCaleb ML, Robson R, et al
    A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy.
    Kidney Int. 2025 Dec 22:S0085-2538(25)01007-5. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
35. GLASSOCK RJ
    Berger disease redux.
    Kidney Int. 2025;108:999-1001.
    PubMed     Abstract available
    
    
    
36. FLOEGE J, Bernier-Jean A, Barratt J, Rovin B, et al
    Corrigendum to "Treatment of patients with IgA nephropathy: a call for a new paradigm." Kidney International 2025;107:640-651.
    Kidney Int. 2025;108:1197-1198.
    PubMed    
    
    
    
37. TAKAHASHI-KOBAYASHI M, Usui J
    THSD7A-positive membranous nephropathy detected by mass spectrometry despite negative immunofluorescence.
    Kidney Int. 2025;108:1191-1192.
    PubMed    
    
    
    November 2025
38. CHRYSOSTOMOU C, Faustini F, Segelmark M, Carrero JJ, et al
    A national cohort study examined the risk of severe infection and infection-related mortality in patients with chronic kidney disease with lupus nephritis in comparison to other chronic kidney disease etiologies.
    Kidney Int. 2025 Nov 21:S0085-2538(25)00883-X. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
39. NASR SH, Caza TN, Larsen CP, Storey A, et al
    Dual-Antigen Membranous Nephropathy.
    Kidney Int. 2025 Nov 4:S0085-2538(25)00862-2. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
40. LIU S, Wu X
    Considerations for fairness and practicality in deep learning model predicting treatment response in lupus nephritis.
    Kidney Int. 2025;108:948.
    PubMed    
    
    
    October 2025
41. ALTUN B, Zhao G, Wang B, Mao X, et al
    Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T-cells.
    Kidney Int. 2025 Oct 31:S0085-2538(25)00855-5. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
42. VILARDELL-VILA J, Jacobs-Cacha C, Martos-Guillami N, Motto AE, et al
    Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr/lpr mice.
    Kidney Int. 2025 Oct 30:S0085-2538(25)00848-8. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
43. GLEESON PJ, Cogne M, Monteiro RC
    Mucin O-glycosylation and B-cell homing: a new bridge for the gut-kidney axis in IgA nephropathy?
    Kidney Int. 2025 Oct 20:S0085-2538(25)00784-7. doi: 10.1016/j.kint.2025.
    PubMed    
    
    
    
44. NAJAFIAN B, Caramori ML, Vestra MD, Saller A, et al
    Heterogeneity in the relationships between albuminuria and glomerular structure in type 1 and type 2 diabetes.
    Kidney Int. 2025 Oct 6:S0085-2538(25)00771-9. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
45. FLOEGE J, Barratt J, Cook HT, Noronha IL, et al
    Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).
    Kidney Int. 2025;108:548-554.
    PubMed     Abstract available
    
    
    
46. THEIS JD, Nasr SH, Sethi S
    Absence of PCDH7-associated dual antigens in membranous nephropathy.
    Kidney Int. 2025;108:707-708.
    PubMed    
    
    
    September 2025
47. ZAHNER G, Dehde S, Seifert L, Huang M, et al
    Patient anti-PLA2R1 autoantibodies cause membranous nephropathy in human PLA2R1 transgenic mice.
    Kidney Int. 2025 Sep 29:S0085-2538(25)00757-4. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
48. JAVAUGUE V, Pascal V, Nasr SH, Bender S, et al
    Revisiting proliferative glomerulonephritis with monoclonal immunoglobulin deposits through immunoglobulin repertoire sequencing.
    Kidney Int. 2025 Sep 24:S0085-2538(25)00751-3. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
49. LAZARETH H, Lenoir O, Garo F, Rocha A, et al
    Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis.
    Kidney Int. 2025 Sep 24:S0085-2538(25)00748-3. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
50. NOVAK L, Hall SD, Cutter G, Gurganus GL, et al
    Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis.
    Kidney Int. 2025 Sep 22:S0085-2538(25)00749-5. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
51. FU R, Wang W, Huo Y, Li L, et al
    Corrigendum to "The mechanosensitive ion channel Piezo1 contributes to podocyte cytoskeleton remodeling and development of proteinuria in lupus nephritis." Kidney International 2024;106:625-639.
    Kidney Int. 2025;108:511-512.
    PubMed    
    
    
    
52. GHASEMI M, Weins A
    Distinguishing signal from noise: a new era of autoantibody testing in podocytopathies requires thoughtful approaches.
    Kidney Int. 2025;108:349-351.
    PubMed     Abstract available
    
    
    August 2025
53. REESE PP, Mohan S, Schaubel DE, Forbes R, et al
    Low prevalence of glomerulonephritis in transplanted kidneys from deceased donors with active hepatitis C virus infection.
    Kidney Int. 2025 Aug 22:S0085-2538(25)00657-X. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
54. CHAN EY, Marks SD
    Childhood-onset lupus nephritis: unique aspects and challenges in management.
    Kidney Int. 2025 Aug 20:S0085-2538(25)00645-3. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
55. AL-RABADI LF, Beck LH Jr
    The podocyte gets a pedicure: tiny nail clippers for podocyte foot processes.
    Kidney Int. 2025;108:176-178.
    PubMed     Abstract available
    
    
    
56. SONG ZR, Liu ZY, Li MS, Li Y, et al
    Expanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy.
    Kidney Int. 2025;108:317-320.
    PubMed     Abstract available
    
    
    
57. ROSENBAUM D, Reichelt J, Gudaitis S, Kuhne S, et al
    Regulation of podocyte surface proteins by the enzyme A Disintegrin And Metalloproteinase 10 (ADAM10).
    Kidney Int. 2025;108:214-232.
    PubMed     Abstract available
    
    
    July 2025
58. HEERINGA P, Rutgers A
    Triggering trouble: post-translational modifications may drive myeloperoxidase autoimmunity.
    Kidney Int. 2025 Jul 14:S0085-2538(25)00480-6. doi: 10.1016/j.kint.2025.
    PubMed    
    
    
    
59. HOU W, Yao Y, Dun D, Xia Y, et al
    Q fever endocarditis and glomerulonephritis.
    Kidney Int. 2025;108:156.
    PubMed    
    
    
    June 2025
60. MASOUD S, Wong K, Pitcher D, Downward L, et al
    Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry.
    Kidney Int. 2025 Jun 27:S0085-2538(25)00491-0. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
61. FLOEGE J, Lafayette R, Barratt J, Schwartz B, et al
    Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy.
    Kidney Int. 2025 Jun 26:S0085-2538(25)00488-0. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
62. CAZA TN, Arivett BA, Hassen SI, Al-Rabadi LF, et al
    Detection and Characterization of NELL1 Autoantibodies in NELL1 Positive Membranous Nephropathy.
    Kidney Int. 2025 Jun 18:S0085-2538(25)00481-8. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
63. LIU P, Liu S, Dalal V, Lane J, et al
    Evaluation of Methodologies in Anti-nephrin Autoantibody Detection.
    Kidney Int. 2025 Jun 7:S0085-2538(25)00430-2. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
64. ZAND L, Russo I, Vargas-Brochero MJ, Nasr SH, et al
    Phospholipase A2receptor-positive membranous nephropathy detected by laser microdissection and mass spectrometry in patients negative by immunofluorescence for phospholipase A2receptor on kidney biopsy.
    Kidney Int. 2025 Jun 6:S0085-2538(25)00428-4. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    May 2025
65. KOOIENGA L, Lee EY, Kim SG, Thomas H, et al
    Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy.
    Kidney Int. 2025 May 30:S0085-2538(25)00414-4. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
66. HANNA C, Basiaga ML, Kastl JT, Caza TN, et al
    PCSK6-associated membranous nephropathy in an adolescent with Sjogren disease.
    Kidney Int. 2025;107:940-942.
    PubMed    
    
    
    
67. BELMONT HM
    Lupus nephritis treat to target normalizing anti-dsDNA, C3, and C4 is a bridge too far.
    Kidney Int. 2025;107:937.
    PubMed    
    
    
    
68. BENYAHIA R, Gueye S, Colombat M, Chauveau D, et al
    Glomerular deposits of neuron-derived neurotrophic factor in a case of membranous nephropathy lacking syphilis signature.
    Kidney Int. 2025;107:935-936.
    PubMed    
    
    
    April 2025
69. OSTENDORF L, Rao DA
    ILC1s drive tissue-aggressive macrophages in experimental lupus nephritis.
    Kidney Int. 2025 Apr 28:S0085-2538(25)00262-5. doi: 10.1016/j.kint.2025.
    PubMed    
    
    
    
70. PAWLUCZYK IZ, Bhachu JS, Brown JR, Lacey M, et al
    B cell-derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy.
    Kidney Int. 2025 Apr 21:S0085-2538(25)00324-2. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
71. JERKE U, Eulenberg-Gustavus C, Wagner DL, Schreiber A, et al
    CRISPR-Cas9 mediated proteinase 3 autoantigen deletion as a treatment strategy for anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
    Kidney Int. 2025 Apr 21:S0085-2538(25)00325-4. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
72. EGGENHUIZEN PJ, Ng BH, Lo C, Chang J, et al
    Engineered antigen-specific T regulatory cells suppress autoreactivity to the anti-glomerular basement membrane disease antigen.
    Kidney Int. 2025;107:751-756.
    PubMed     Abstract available
    
    
    
73. SHIRAI Y, Miura K, Morimoto K, Yokoo T, et al
    Reevaluating anti-nephrin autoantibodies by ELISA using human embryonic kidney-derived recombinant extracellular domain of human nephrin.
    Kidney Int. 2025;107:757-759.
    PubMed    
    
    
    March 2025
74. ROUSSELLE A, Lodka D, Sonnemann J, Kling L, et al
    Endothelial but not systemic ferroptosis inhibition protects from antineutrophil cytoplasmic antibody-induced crescentic glomerulonephritis.
    Kidney Int. 2025 Mar 21:S0085-2538(25)00250-9. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
75. ODLER B, Riedl R, Geetha D, Szpirt WM, et al
    The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial.
    Kidney Int. 2025;107:558-567.
    PubMed     Abstract available
    
    
    
76. SHAH SI, Paudel S, Dalland JC, McPhail EM, et al
    Concurrent AL amyloidosis and fibrillary glomerulonephritis.
    Kidney Int. 2025;107:579.
    PubMed    
    
    
    February 2025
77. HENGEL FE, Dehde S, Yilmaz A, Bayazit AK, et al
    Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy.
    Kidney Int. 2025 Feb 6:S0085-2538(25)00082-1. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    January 2025
78. FLOEGE J, Bernier-Jean A, Barratt J, Rovin B, et al
    Treatment of Patients with IgA Nephropathy: A call for a new paradigm.
    Kidney Int. 2025 Jan 31:S0085-2538(25)00076-6. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
79. PRUNOTTO M, Nachman PH, Gillespie BS, Beck LH Jr, et al
    Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop.
    Kidney Int. 2025 Jan 28:S0085-2538(24)00776-2. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
80. CANNEY M, Atiquzzaman M, Zheng Y, Induruwage D, et al
    Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases.
    Kidney Int. 2025;107:143-154.
    PubMed     Abstract available
    
    
    December 2024
81. CHENG C, Li B, Li J, Wang Y, et al
    Multi-stain deep learning prediction model of treatment response in lupus nephritis based on renal histopathology.
    Kidney Int. 2024 Dec 27:S0085-2538(24)00923-2. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
82. FOLESTAD E, Mehlem A, Ning FC, Oosterveld T, et al
    Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.
    Kidney Int. 2024 Dec 15:S0085-2538(24)00872-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    November 2024
83. AL-AUBODAH TA, Piccirillo CA, Trachtman H, Takano T, et al
    The autoimmune architecture of childhood idiopathic nephrotic syndrome.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00804-4. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
84. KASINATH V, Tsokos GC
    PI3Kalpha in the pathogenesis and treatment of lupus nephritis.
    Kidney Int. 2024 Nov 16:S0085-2538(24)00794-4. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
85. DE VRIESE AS, Sethi S, Fervenza FC
    Lupus Nephritis: Redefining the treatment goals.
    Kidney Int. 2024 Nov 7:S0085-2538(24)00781-6. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
86. LARKINS NG, Craig JC
    Using prediction models to improve care and communicate risk: updated modeling for children with IgA nephropathy.
    Kidney Int. 2024;106:790-792.
    PubMed     Abstract available
    
    
    
87. HU P, Xiao H, Alba MA, Atkins HM, et al
    Myeloperoxidase-ANCA IgG induces different forms of small vessel vasculitis based on type of synergistic immune stimuli.
    Kidney Int. 2024;106:870-886.
    PubMed     Abstract available
    
    
    
88. CHEUNG CK, Barratt J, Lafayette R, Liew A, et al
    Targeting APRIL in the treatment of glomerular diseases.
    Kidney Int. 2024;106:806-818.
    PubMed     Abstract available
    
    
    October 2024
89. MACHALITZA M, Debiec H, Krumpelmann B, Ferru N, et al
    PCDH7-antibodies and PCDH7 immune deposits are mostly found in patients with PLA(2)R1- or NELL1-associated membranous nephropathy.
    Kidney Int. 2024 Oct 24:S0085-2538(24)00725-7. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
90. VODEHNAL S, Mohan C
    Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.
    Kidney Int. 2024 Oct 4:S0085-2538(24)00696-3. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
91. ROSALES IA, Zhou IY, Ay I, Sojoodi M, et al
    Imaging kidney inflammation using an oxidatively activated MRI probe.
    Kidney Int. 2024;106:671-678.
    PubMed     Abstract available
    
    
    
92. HATTORI M
    Anti-nephrin autoantibodies: novel predictors of post-transplant recurrence of focal segmental glomerular sclerosis.
    Kidney Int. 2024;106:570-572.
    PubMed     Abstract available
    
    
    September 2024
93. CHEN Z, Li X, Li C, Cai J, et al
    The significance of subclassifying focal segmental glomerulosclerosis lesions (S1) in IgA nephropathy.
    Kidney Int. 2024;106:540.
    PubMed    
    
    
    August 2024
94. SELVASKANDAN H, Barratt J
    The mucosal microbiome and IgA nephropathy: a new target for treatment?
    Kidney Int. 2024 Aug 29:S0085-2538(24)00621-5. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
95. VRANA JA, Theis JD, Wegwerth PJ, Dasari S, et al
    A reliable clinical test for detection of membranous nephropathy antigens using laser microdissection and mass spectrometry.
    Kidney Int. 2024 Aug 26:S0085-2538(24)00618-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
96. SETHI S, Madden B, Moura MC, Nasr SH, et al
    FAT1 is a target antigen in a subset of de novo allograft membranous nephropathy associated with antibody mediated rejection.
    Kidney Int. 2024 Aug 22:S0085-2538(24)00569-6. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    July 2024
97. BARBOUR SJ, Coppo R, Er L, Russo ML, et al
    Application of the updated International IgA Nephropathy Prediction Tool in children one- or two-years post-biopsy.
    Kidney Int. 2024 Jul 31:S0085-2538(24)00532-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
98. FU R, Wang W, Huo Y, Li L, et al
    The mechanosensitive ion channel Piezo1 contributes to podocyte cytoskeleton remodeling and development of proteinuria in lupus nephritis.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00529-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
99. CHOU YL, Chen HL, Hsu BG, Yang CY, et al
    Galectin-3 contributes to pathogenesis of IgA nephropathy.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00527-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    June 2024
100. TANG J, Xiao Z, Liu L, Li X, et al
     Renal artery microaneurysms in antineutrophil cytoplasmic antibody-associated vasculitis.
     Kidney Int. 2024;105:1326.
     PubMed    
     
     
     
101. ROVIRA J, Arana C, Garcia-Busquets A, Gille I, et al
     Chimeric autoantibody receptor cell therapy for the treatment of membranous nephropathy.
     Kidney Int. 2024;105:1320.
     PubMed    
     
     
     
102. HAAS M
     Podocyte injury as a potential therapeutic target in IgA nephropathy: should pathology guide us?
     Kidney Int. 2024;105:1165-1167.
     PubMed     Abstract available
     
     
     
103. UEDA Y, Nakazawa D, Nishio S, Shiratori-Aso S, et al
     Transcription factor Nrf2 activation regulates NETosis, endothelial injury, and kidney disease in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis.
     Kidney Int. 2024;105:1291-1305.
     PubMed     Abstract available
     
     
     May 2024
104. ABBAD L, Detrait M, Kavvadas P, Bergonnier D, et al
     Signaling through cAMP-Epac1 induces metabolic reprogramming to protect podocytes in glomerulonephritis.
     Kidney Int. 2024 May 29:S0085-2538(24)00380-6. doi: 10.1016/j.kint.2024.
     PubMed     Abstract available
     
     
     April 2024
105. NARAYANAN R, Sivadas S, Kurien AA
     NELL-1 associated membranous nephropathy linked to skin fairness cream use- insights from an Indian case series.
     Kidney Int. 2024 Apr 12:S0085-2538(24)00263-1. doi: 10.1016/j.kint.2024.
     PubMed    
     
     
     
106. SELVASKANDAN H, Barratt J
     Charting new frontiers in IgA nephropathy: a paradigm shift toward precision medicine and early intervention?
     Kidney Int. 2024;105:659-661.
     PubMed     Abstract available
     
     
     March 2024
107. BELLUR SS, Troyanov S, Vorobyeva O, Coppo R, et al
     Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy.
     Kidney Int. 2024 Mar 28:S0085-2538(24)00235-7. doi: 10.1016/j.kint.2024.
     PubMed     Abstract available
     
     
     
108. LAFAYETTE R, Barbour S, Israni R, Wei X, et al
     A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
     Kidney Int. 2024 Mar 27:S0085-2538(24)00236-9. doi: 10.1016/j.kint.2024.
     PubMed     Abstract available
     
     
     
109. WANG H, Zuiani J, Coates Ao PT, Xia Y, et al
     Reconstructing the interface between the human intestine and immune system: potential to advance mechanistic studies in IgA nephropathy.
     Kidney Int. 2024;105:423-426.
     PubMed    
     
     
     
110. FLOEGE J, Jayne DRW, Sanders JF, Tesar V, et al
     Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis.
     Kidney Int. 2024;105:447-449.
     PubMed     Abstract available
     
     
     
111. 
     KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
     Kidney Int. 2024;105.
     PubMed    
     
     
     February 2024
112. VOINESCU CD, Mozere M, Genovese G, Downie ML, et al
     A Neanderthal haplotype introgressed into the human genome confers protection against membranous nephropathy.
     Kidney Int. 2024 Feb 14:S0085-2538(24)00073-5. doi: 10.1016/j.kint.2024.
     PubMed     Abstract available
     
     
     
113. TANIGUCHI T, Hiwa R, Morinobu A
     Pitfalls in evaluating the impact of persistent hematuria after induction therapy on kidney prognosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
     Kidney Int. 2024;105:391-392.
     PubMed    
     
     
     
114. WIMBURY D, Muto M, Bhachu JS, Scionti K, et al
     Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial.
     Kidney Int. 2024;105:381-388.
     PubMed    
     
     
     
115. SEIFERT L, Riecken K, Zahner G, Hambach J, et al
     An antigen-specific chimeric autoantibody receptor NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells.
     Kidney Int. 2024 Feb 1:S0085-2538(24)00080-2. doi: 10.1016/j.kint.2024.
     PubMed    
     
     
     January 2024
116. WANG H, Shen M, Ma Y, Lan L, et al
     Novel mitophagy inducer alleviates lupus nephritis by reducing myeloid cell activation and autoantigen presentation.
     Kidney Int. 2024 Jan 29:S0085-2538(24)00064-4. doi: 10.1016/j.kint.2023.
     PubMed     Abstract available
     
     
     
117. ROVIN BH, Ayoub IM, Chan TM, Liu ZH, et al
     Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
     Kidney Int. 2024;105:31-34.
     PubMed     Abstract available
     
     
     
118. FLOEGE J
     A new alternative: inhibiting complement activation in patients with IgA nephropathy.
     Kidney Int. 2024;105:28-30.
     PubMed     Abstract available
     
     
     
119. 
     KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.
     Kidney Int. 2024;105.
     PubMed    
     
     
     
120. LUCIENTES-CONTINENTE L, Fernandez-Juarez G, Marquez-Tirado B, Jimenez-Villegas L, et al
     Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
     Kidney Int. 2024;105:177-188.
     PubMed     Abstract available
     
     
     
121. DYLEWSKI JF, Haddad G, Blaine J
     Exploiting the neonatal crystallizable fragment receptor to treat kidney disease.
     Kidney Int. 2024;105:54-64.
     PubMed     Abstract available
     
     
     December 2023
122. RIVEDAL M, Mikkelsen H, Marti HP, Liu L, et al
     Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy.
     Kidney Int. 2023 Dec 26:S0085-2538(23)00920-1. doi: 10.1016/j.kint.2023.
     PubMed     Abstract available
     
     
     
123. KISTLER AD, Salant DJ
     Complement Activation and Effector Pathways in Membranous Nephropathy.
     Kidney Int. 2023 Dec 21:S0085-2538(23)00868-2. doi: 10.1016/j.kint.2023.
     PubMed     Abstract available
     
     
     
124. ROBSON KJ
     Laminin-521: a novel target for pathogenic autoantibodies in anti-glomerular basement membrane disease.
     Kidney Int. 2023;104:1054-1056.
     PubMed     Abstract available
     
     
     November 2023
125. BECK LH JR
     The latest model has just arrived! A new experimental mouse model of PLA2R1-associated membranous nephropathy.
     Kidney Int. 2023;104:878-880.
     PubMed     Abstract available
     
     
     
126. LEE M, Suzuki H, Ogiwara K, Aoki R, et al
     The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy.
     Kidney Int. 2023;104:943-955.
     PubMed     Abstract available
     
     
     October 2023
127. ZHANG H, Rizk DV, Perkovic V, Maes B, et al
     Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
     Kidney Int. 2023 Oct 30:S0085-2538(23)00754-8. doi: 10.1016/j.kint.2023.
     PubMed     Abstract available
     
     
     
128. KIM M, Kim SS, Choi HI, Choi HS, et al
     Cryofibrinogen-associated membranoproliferative glomerulonephritis.
     Kidney Int. 2023;104:860.
     PubMed    
     
     
     
129. TANIGUCHI T, Hiwa R, Morinobu A
     The conclusion that myeloperoxidase inhibition is not protective against anti-neutrophil cytoplasmic autoantibody-associated vasculitis is premature.
     Kidney Int. 2023;104:856.
     PubMed    
     
     
     September 2023
130. SETHI S, Beck LH Jr, Glassock RJ, Haas M, et al
     Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.
     Kidney Int. 2023 Sep 6:S0085-2538(23)00490-8. doi: 10.1016/j.kint.2023.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum